 | |||
      |
|
James H. Cavanaugh, Ph.D. Princeton James Cavanaugh has been a Managing Director of HealthCare Ventures since 1988. He was previously president of SmithKline & French Laboratories–U.S., the domestic pharmaceutical division of SmithKline Beckman Corporation. He had been president of SmithKline Beckman’s clinical laboratory business and president of Allergan International. Earlier Dr. Cavanaugh served in numerous senior posts with the U.S. Government on the White House staff and before that at the U.S. Department of Health and Human Services. Prior to that he was a member of the faculty of the College of Medicine and the Graduate College at the University of Iowa. Dr. Cavanaugh received his Master's and Doctorate degrees from the University of Iowa. Cambridge Augustine Lawlor is the Managing Partner of HealthCare Ventures. Prior to joining HealthCare Ventures in 2000, he was chief operating officer of LeukoSite, Inc., a HealthCare Ventures III, IV, and V company. Before joining LeukoSite, Mr. Lawlor was chief financial officer and vice president of corporate development for Alpha-Beta Technology. He held similar positions at BioSurface Technology and Armstrong Pharmaceuticals. Mr. Lawlor has also served as a management consultant with KPMG Peat Marwick. Mr. Lawlor is currently a member of the board of directors of the Slater Center in Providence, Rhode Island. Mr. Lawlor received his Master's degree in public and private management from Yale University. Cambridge John Littlechild has been a Managing Director of HealthCare Ventures since 1992. Prior to joining HealthCare Ventures, he was the founding general partner of Advent International in Boston, after opening the London office of Advent U.K. He also held a similar position at Citicorp Venture Capital. Before his career in venture capital, Mr. Littlechild held marketing and financial management positions with Rank, Xerox and ICI. Mr. Littlechild is a member of the board of fellows of the Council for Harvard Medicine. Mr. Littlechild received his M.B.A. degree from Manchester Business School. Christopher K. Mirabelli, Ph.D. Cambridge Chris Mirabelli joined HealthCare Ventures as a Dr. Mirabelli received his Doctorate degree in molecular pharmacology from Baylor College of Medicine. Cambridge Doug Onsi is a Venture Partner of HealthCare Ventures. Prior to joining HealthCare Ventures in 2007, he served as Vice President, Campath Product Operations & Oncology Portfolio Management and as Vice President, Business Development at Genzyme Corporation. Before joining Genzyme, Mr. Onsi was Chief Financial Officer and Vice President, Business Development of TolerRx, Inc., a company in which HealthCare Ventures was the lead investor. Prior to TolerRx, he held a senior business development position at LeukoSite, Inc., another HealthCare Ventures portfolio company, which was merged with Millennium Pharmaceuticals, Inc. He has also practiced corporate law at Bingham Dana LLP. Mr. Onsi received his J.D. degree from University of Michigan Law School and B.S. degree in biology from Cornell University. Princeton Hal Werner is a Managing Director and Co-founder of HealthCare Ventures. Prior to the formation of HealthCare Ventures, Mr. Werner served as director of new ventures for Johnson & Johnson Development Corporation. Mr. Werner also has served as senior vice president of Robert S. First, Inc., an international health care consulting firm. Mr. Werner received his M.B.A. degree from Harvard University.
| |
Nothing in this website constitutes an offer to sell, or a solicitation of an offer to buy, any securities.Rev 11/2007 ©1990-2007 HealthCare Ventures LLC | |||